"It is a serious disservice to British and international medicine," Collins told the Guardian at the time, claiming that the alarm caused was probably killing more people than had been harmed as a result of the paper on the MMR vaccine by Andrew Wakefield. "I would think the papers on statins are far worse in terms of the harm they have done."
The paper, by John Abramson and colleagues, questioned the decision to extend statins to thousands of people at low risk of heart attacks and strokes, saying that the drugs had not been proven to save lives in that group. They also claimed that an observational study had shown that 18%-20% suffer side effects from statins. An article by cardiologist Aseem Malhotra published the same week repeated the figure. Both authors have now withdrawn that statement.
In an editorial published in the BMJ, author Dr Fiona Godlee said the error was due to a misreading of the data from the study and was not picked up by the peer review process. "The BMJ and the authors of both these articles have now been made aware that this figure is incorrect, and corrections have been published withdrawing these statements," she writes.
Advertisement
Writing, peer reviewing and editing are all subject to human error, she says, "which is why we must be, and are, ready to correct things when they are found to be wrong".
Collins, however, wants the paper and the article that the BMJ published to be retracted. Godlee has referred this to an independent panel to decide, saying that the remainder of the articles remain valid.
"My point is that this is a serious misrepresentation of the scientific evidence and has substantial public health impact," Collins said. The erroneous side effects claims were being repeated around the world, he claimed, and would continue to be made unless the papers were withdrawn.
Prof Peter Weissberg, medical director at the British Heart Foundation, said it welcomed "the BMJ's retraction of incorrect statements on the side effects of statins". He said: "Statins are an important weapon in the fight against heart disease and it is essential that trusted medical journals like the BMJ do not mislead the public. Patients should feel reassured by this move and should not stop taking their statin."
John Greenwood, professor of biomedical research at University College London, said: "There is overwhelming scientific and clinical evidence that statins are an extremely well-tolerated class of drug that provides significant health benefit to a vast number of at risk patients. Despite such overwhelming evidence, there remains a disproportionate and highly public opposition to their use. Much of this concern is based on the view that harmful side effects are not fully reported and this is further strengthened by a plethora of anecdotal 'evidence'.
"It is therefore to be applauded that the BMJ has taken steps to clarify any misconceptions that could arise from publications in which there has been a clear misinterpretation of data. As with all drugs, the sole criteria determining statin use should be whether the risk outweighs the benefit. Consequently, it is incumbent on the scientific and medical community to ensure that data is interpreted in the most rigorous fashion so that such decisions are based on fact and not on spurious assumptions."